What it is
Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, paired with Cagrilintide, a long-acting amylin analog, in a research combination that has not itself been evaluated in any clinical study.
In this article
🧪 Load this blend into the DIY blend calculator →
What it is
Retatrutide (LY3437943) activates three receptors — GLP-1, GIP and glucagon. Cagrilintide is a long-acting amylin analog: a lab-made copy of a natural body-signal molecule, engineered to stay active longer. Amylin signalling runs through the hindbrain and is separate from the incretin pathways retatrutide acts on.
Unlike CagriSema, this pairing has no manufacturer development name and no trial programme. It circulates as a community and vendor combination.
Why these are combined
The argument is pathway separation, and here it is at least structurally sound: an amylin analog and an incretin agonist act through different signalling routes, so the pairing is not the redundant stack that two incretin agonists together would be.
The precedent people reason from is CagriSema, where adding an amylin analog to a GLP-1 backbone was formally tested. Substituting a triple agonist for that backbone is an extrapolation from those results, not a finding of its own.
Key point: Amylin and incretin signalling are genuinely distinct pathways, which is why this pairing is discussed. The reasoning is borrowed from CagriSema trials; this specific combination has not itself been studied.
What is not known
Retatrutide’s published phase 2 obesity data describes retatrutide alone. Cagrilintide’s combination evidence comes from pairing it with semaglutide, not with retatrutide.
For this pairing specifically there is no published trial, no pharmacokinetic work on the two together, no co-formulation stability data, and no established ratio. Vendor listings that pair a given milligram split with the combination are describing a product decision.
The components
- Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, studied on its own for effects on body weight and metabolic markers.
- Cagrilintide, a long-acting amylin analog, studied for its effect on appetite signalling.
Reconstitution and blending
These research compounds arrive as a dry powder. At the bench the powder is reconstituted (dissolved into a liquid solution) using bacteriostatic water, a specially purified water with a small preservative added to slow bacterial growth in the vial.
Because this is a combination rather than a single studied formulation, there is no published compatibility or stability work for the two peptides sharing one vessel. Compounds that are individually stable can degrade faster together, and any multi-compound mixture shortens a conservative beyond-use window. Where compatibility is unknown, the conservative bench practice is to reconstitute separately.
Our reconstitution and DIY blend calculators handle the per-cartridge volumes and beyond-use timing once you have decided what shares a cartridge.
Status in sport
WADA (the World Anti-Doping Agency) maintains the list of substances banned in competitive sport. Incretin compounds in this family are not currently on the WADA Prohibited List.
As of the 2026 cycle, GLP-1 compounds appear on the WADA Monitoring Program — tracked and watched, but not banned. This status can change in future list cycles, so verify it independently against the current year’s list.
Related reading
- Retatrutide
- Cagrilintide
- CagriSema — the studied amylin plus GLP-1 pairing
- Full peptide reference library and stacking guide
- Reconstitution and blend calculators
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
Has Retatrutide plus Cagrilintide been studied in a clinical trial?
No. Retatrutide has published phase 2 data on its own, and cagrilintide has combination data with semaglutide, but no clinical study has evaluated retatrutide together with cagrilintide.
How does this differ from CagriSema?
CagriSema is Novo Nordisk’s development name for cagrilintide plus semaglutide, a fixed combination with its own trial programme. Substituting retatrutide for semaglutide changes the incretin component from a GLP-1 agonist to a triple GLP-1/GIP/glucagon agonist, and that substitution has not been formally tested.
Do amylin analogs and incretin agonists act on the same pathway?
No. Amylin signalling runs through the hindbrain, while GLP-1, GIP and glucagon agonism act through incretin and glucagon receptors. That separation is the stated reason the two classes are discussed together.
Are these compounds banned under WADA rules for 2026?
GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited, and amylin agonists are not on the Prohibited List. Verify against the current year’s list, since classification can change.
What the research community gets wrong about Retatrutide + Cagrilintide
- CagriSema results are not this pairing’s results. The trial evidence people cite tested cagrilintide with semaglutide. Swapping in a triple agonist is an untested change, not a stronger version of the same study.
- It is two peptides, not one. At the bench you are handling two separate research compounds. Label and track each one rather than treating the vial as a single ingredient.
- A vendor code name is not a specification. These pairings circulate under opaque product names that differ from seller to seller, and most sellers do not publish what is actually in them. A code name tells you nothing about identity, ratio, or purity — only an assay does.
- Single-compound trial data does not transfer to a combination. Published results describe one compound studied on its own, under a protocol. They say nothing about what two compounds do together, and nothing about a solution reconstituted at a bench.
- A reconstituted vial does not stay good forever. Peptides in solution break down over time, and rough handling (shaking hard enough to foam) can damage them. Note your reconstitution date and store the vial as your protocol calls for.
From our bench: If you have reconstituted a vial of this pairing, tell us what you actually observed. How long did the powder take to fully dissolve in bacteriostatic water, was the final solution clear or cloudy, and did any particles or haze appear after it sat cold? Share your own logged observations, not numbers copied from a label, so other researchers can compare notes.
Sources
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med, 2023
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med, 2025. PMID 40544433
- PubChem Compound Summary: Cagrilintide
- Bacteriostatic Water for Injection, USP — FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 — Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) — Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
